Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19088118 | 0.88 | KDM4E (0.43) | FFAR4MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19078423 | 0.87 | MAPT (0.43) | NOTUMFFAR4MAPTCYP1A2CYP3A4 | |
| SCHEMBL19078405 | 0.87 | FFAR4 (0.39) | NOTUMFFAR4MAPTCYP1A2CYP3A4 | |
| SCHEMBL17305174 | 0.86 | LMNA (0.44) | NOTUMFFAR4MAPTCYP1A2CYP3A4 | |
| SCHEMBL19078396 | 0.85 | MAPT (0.43) | NOTUMFFAR4MAPTCYP1A2CYP3A4 | |
| SCHEMBL19088117 | 0.84 | NOTUM (0.42) | NOTUMFFAR4MAPTCYP1A2CYP3A4 | |
| SCHEMBL19078487 | 0.84 | NOTUM (0.42) | NOTUMFFAR4MAPTCYP1A2CYP3A4 | |
| SCHEMBL19078390 | 0.84 | MAPT (0.42) | NOTUMFFAR4MAPTCYP1A2CYP3A4 | |
| SCHEMBL19088120 | 0.83 | FFAR4 (0.40) | NOTUMFFAR4MAPTCYP1A2CYP3A4 | |
| SCHEMBL19078474 | 0.82 | ENPP2 (0.42) | NOTUMFFAR4MAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190697-A1 | NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST | MC1R, MC5R, MC3R | NOTUM 2699/4885FFAR4 295/4885MAPT 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.